Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

FDA Panel Recommends Approval Of Chelsea Therapeutics' Northera

RELATED NEWS
Trade CHTP now with 

Chelsea Therapeutics International Ltd.(CHTP: Quote) announced that the Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee or CRDAC voted 7-4 with 1 abstention and 1 non-vote to recommend approval of Northera (droxidopa) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with primary autonomic failure (Parkinson's disease, multiple system atrophy and pure autonomic failure), dopamine beta hydroxylase deficiency and non-diabetic autonomic neuropathy.

A Prescription Drug User Fee Act (PDUFA) action date for the Northera NDA has been scheduled for March 28, 2012.

Click here to receive FREE breaking news email alerts for Chelsea Therapeutics International and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
U.S. stocks edged higher on Tuesday, with the S&P 500 posting its first-ever finish above the 2,000 mark as strong economic data and a flurry of merger news contributed to buying interest. Led by energy stocks, the S&P 500 rose 2.1 points, or 0.1%, to 2,000.02 after touching an intraday record just... South Africa's leading index rose for the second straight month in June, figures from the South African Reserve Bank showed Tuesday. The composite leading index, which measures perception on future economic conditions, rose by 0.5 percent to 100.1 in June from 99.6 in the previous month. Out of ten... German business sentiment weakened for the fourth consecutive month to the lowest level in a year in August, as the escalating crisis in Ukraine and the resultant sanctions against Russia pose downside risks to the economic activity. The Ifo business climate index fell to 106.3 in August, the lowest since July 2013, from 108 a month ago, a monthly survey conducted by the Ifo institute showed.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.